Abstract Spinal cord injury (SCI) causes not only sensorimotor and cognitive deficits, but frequently also severe chronic pain that is difficult to treat (SCI pain). We previously showed that hyperesthesia, as well as spontaneous pain induced by electrolytic lesions in the rat spinothalamic tract, is associated with increased spontaneous and sensory-evoked activity in the posterior thalamic nucleus (PO). We have also demonstrated that rodent impact SCI increases cell cycle activation (CCA) in the injury region and that post-traumatic treatment with cyclin dependent kinase inhibitors reduces lesion volume and motor dysfunction. Here we examined whether CCA contributes to neuronal hyperexcitability of PO and hyperpathia after rat contusion SCI, as well as to microglial and astroglial activation (gliopathy) that has been implicated in delayed SCI pain. Trauma caused enhanced pain sensitivity, which developed weeks after injury and was correlated with increased PO neuronal activity. Increased CCA was found at the thoracic spinal lesion site, the lumbar dorsal horn, and the PO. Increased microglial activation and cysteine-cysteine chemokine ligand 21 expression was also observed in the PO after SCI. In vitro, neurons co-cultured with activated microglia showed up-regulation of cyclin D1 and cysteine-cysteine chemokine ligand 21 expression. In vivo, post-injury treatment with a selective cyclin dependent kinase inhibitor (CR8) significantly reduced cell cycle protein induction, microglial activation, and neuronal activity in the PO nucleus, as well as limiting chronic SCI-induced hyperpathia. These results suggest a mechanistic role for CCA in the development of SCI pain, through effects mediated in part by the PO nucleus. Moreover, cell cycle modulation may provide an effective therapeutic strategy to improve reduce both hyperpathia and motor dysfunction after SCI.
Introduction
Traumatic spinal cord injury (SCI) is a leading cause of paralysis, and may lead to other catastrophic consequences, including compromised bladder and bowel functions [1] , emotional and psychological distress [2] , and loss of sexual function [3] . SCI results not only in debilitating motor and sensory, but also in chronic, hyperpathic pain (SCI pain). Such pain can be diffuse or bilateral, and often extends to locations caudal to the spinal injury ("below-lesion") [4] [5] [6] . Perhaps most debilitating is the presence in most patients of chronic, spontaneous pain [7, 8] . SCI pain is usually resistant to treatment [9] . In most SCI patients chronic pain first appears more than 1 year after the injury [10] [11] [12] . The delayed expression of SCI pain, the diffuse localization of painful symptoms, and the presence of pain below the denervated spinal segment strongly suggest the occurrence of maladaptive plasticity not only in the spinal cord, but also in supraspinal structures [13] . The latent period between the spinal injury and the development of chronic pain provides a window of opportunity for interventions to prevent or minimize the development of SCI pain. Discovering new interventions to manage SCI pain requires a better understanding of the physiological mechanisms underlying the development of related maladaptive sensory plasticity after injury.
Chronic pain syndromes (CPS), including SCI pain, have long been suspected to involve the thalamus [14] [15] [16] . There are SCI-induced changes in several thalamic nuclei, including intralaminar, mediodorsal, ventral, and posterior nuclei [13, 17] . Activity of neurons and microglia in the ventroposteriolateral nucleus (VPL) appear to be abnormally increased in association with SCI pain [18] [19] [20] [21] . The posterior nucleus (PO) of the thalamus receives convergent innocuous and noxious somatosensory inputs by way of the spinothalamic tract (STT), the major ascending pain pathway [22, 23] . We have previously reported increased spontaneous and sensory-evoked activity in PO that is associated with CPS induced by unilateral focal electrolytic lesions in the rat STT [24] . We also provided evidence that these changes are caused by reduced inhibitory inputs to PO, and that they are causally related to the experience of pain in these animals [13] .
After SCI, chronic activation of microglia and astrocytes are found at the lesion site, caudal dorsal horn, and thalamus [21, [25] [26] [27] [28] [29] [30] . Such changes have been implicated in the induction and maintenance of SCI pain. Identification of molecular mechanisms underlying this "gliopathy" [29, 31, 32] may therefore help to clarify the pathobiology of SCI pain and lead to the elucidation of novel therapeutic targets.
Cell cycle activation (CCA) contributes to both astroglial and microglial activation after central nervous system injuries, including SCI [33, 34] . In addition, cyclin dependent kinase (CDK) inhibitors can reduce neuronal death, suppress reactive glia, and improve neurological outcomes in a number of acute and chronic neurodegenerative disorders [33, [35] [36] [37] [38] [39] [40] [41] [42] [43] . Little is known about the role of cell cycle genes in neuropathic pain. Recently, the pan-CDK inhibitor, flavopiridol, administered intrathecally, was reported to reduce tactile allodynia after spinal nerve injury through inhibition of astrocyte proliferation [44] . Roscovitine, a more selective CDK inhibitor, reduced heat-induced hyperalgesia induced by complete Freund's adjuvant or formalin-induced nociceptive responses in rats [45, 46] . In the present study, we examined the effects of impact SCI in rats on the development of SCI pain, the potential role of the PO in mediating such pain, and whether CCA contributed to the development of post-traumatic hyperpathia and associated glial alterations.
Materials and Methods
All procedures were conducted according to Animal Welfare Act regulations and public health service (PHS) guidelines. Strict aseptic surgical procedures were used, according to the guidelines of the International Association for the Study of Pain, and approved by the University of Maryland School of Medicine Animal Care and Use Committee.
Spinal Cord Injury and Drug Administration
Adult male Sprague-Dawley rats weighing 275-325 g were anesthetized with sodium pentobarbital (65 mg/kg i.p.). Body temperature was kept by maintaining the animal on a heating pad (37°C) throughout the procedure. Spinal contusion injury was produced at spinal segment T10 using our wellcharacterized rat impact injury device [30, 47] . A 10-g weight was dropped from a height of 2.5 cm onto the exposed spinal cord without disrupting the dura. Sham-injured rats received a laminectomy without trauma. Post-operatively, rats were injected subcutaneously with 5 ml of 0.9 % saline and allowed to recover on a heating pad. Bladders were manually expressed twice a day until reflex bladder emptying was established, typically by 10-14 d after injury. After SCI, rats were assigned to a treatment group according to a randomized block experimental design. The number of rats at various time points in each study is indicated in the figures legends. CR8 (Tocris Bioscience, Ellisville, MO, USA) was dissolved in sterile saline and administered intraperitoneally, once daily beginning 3 h post-injury and continuing for 7 days. Groups of rats received 1 mg/kg CR8 or the equivalent volume of saline. This dose of CR8 was based upon prior investigations in SCI model [30, 46] . In addition, we have reported that systemic flavopiridol treatment (1 mg/kg) administered daily for 1 week following SCI enhanced functional recovery [43] . We now have evidence that anti-apoptotic concentrations of CR8 in cultured cortical neurons were similar to those of flavopiridol, a potent pan-CDK inhibitor. The effect of CR8 on microglial proliferation and activation in response to LPS in cultured primary microglia was also similar to that of flavopiridol.
Behavioral Assessments
Open-Field Test (Basso, Beattie, and Bresnahan Scores)
Rats were assessed for hind limb function in open field locomotion on day 1 post-injury and weekly thereafter for up to 5 weeks, using the Basso, Beattie and Bresnahan (BBB) open field expanded locomotor score [48] .
Combined Behavioral Score
Neurological functional deficits were also estimated with a combined behavioral score (CBS), which included open field locomotion (motor score); withdrawal reflex to hind limb extension, pain and pressure; foot placing, toe spread and righting reflexes; maintenance of position on an inclined plane; and swimming tests [49] .
Hind Paw Mechanical Withdrawal Thresholds
All animals were tested on 3 consecutive days before the SCI, at day 21 after surgery, and at weekly intervals thereafter, until electrophysiological data were collected. To minimize the animals' anxiety they were habituated for 2 days before behavioral testing. Mechanical withdrawal thresholds were measured using the Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, VA, Italy) at a ramp speed of 5 g/s. Force at the time of paw withdrawal was measured over 3 trials on a testing day for each hindpaw and averaged. Postsurgery percent change in thresholds from baseline was calculated for each hindpaw and averaged for a bilateral measure of algesia for each animal.
Extracellular Recordings
At least 45 days after SCI, rats were anesthetized with urethane and prepared for extracellular recordings as previously described [24, 50] . We selected urethane because it has no, or negligible, effects on glutamatergic and gamma-aminobutryic acid (GABA)ergic transmission, and therefore produces only minimal disruption of signal transmission [51] . We administered 20 % urethane intraperitoneally at intervals to maintain the animal at level III-2, as described by Friedberg et al. [52] with a total dose not exceeding 1.5 mg/kg. Anesthetic levels were monitored continually using respiration rate; vibrissae movement; and hindpaw pinch, corneal, and eyelid reflexes.
Extracellular recordings were obtained from PO thalamus through quartz-insulated tungsten electrodes (1-4 MΩ). We recorded from well-isolated units, digitized (40 kHz) the waveforms through a Plexon (Dallas, TX, USA) dataacquisition system, and sorted units off-line with Plexon's off-line sorter, using dual thresholds and principle component analyses. We generated autocorrelograms with Neuroexplorer software (Plexon) to confirm that we obtained recordings from single units. We exported time stamps of well-isolated units and stimulus triggers to Matlab (MathWorks, Natick, MA, USA) for analyses using custom-written algorithms.
Tissue Processing and Histopathology
At specific times after injury, rats were deeply anesthetized with sodium pentobarbital (100 mg/kg i.p.) and transcardially perfused with 200 ml of normal saline followed by 500 ml of PBS containing 4 % paraformaldehyde (PH 7.4). The brain and spinal cord were removed, postfixed in 4 % paraformaldehyde overnight, and transferred to 30 % sucrose at 4°C. Coronal sections were cut with a cryostat and thaw-mounted onto Superfrost Plus slides (Fisher Scientific, Pittsburg, PA, USA).
Assessment of White Matter Sparing
Every twentieth slide from each set was stained with eriochrome cyanine (ECRC) and residual white matter (WM) area was calculated at the injury epicenter, as well as at points rostral and caudal to the epicenter by quantifying the total area stained by ECRC. Images were taken at 2.5× magnification and analyzed using NIH ImageJ software. The threshold level of each 8-bit image was set to display only ECRC-positive pixels, and total ECRC-positive area was calculated for each section. 43 The lesion epicenter was defined as the section with the least amount of spared WM.
Estimation of Lesion Volume
Lesion volume was assessed using the Stereologer 2000 software (Systems Planning and Analysis, Alexandria, VA, USA) [30] . Sections spaced 1 mm apart from 5 mm caudal to 5 mm rostral the injury epicenter were stained with glial fibrillary acidic protein (GFAP) and diaminobenzidine (DAB) as the chromogen for lesion volume assessment based on the Cavalieri method of unbiased stereology with a grid spacing of 200 μm.
Stereological Quantification of Microglial Phenotypes
StereoInvestigator Software (MBF Biosciences, Williston, VT, USA) was used to count the number of the three microglial morphological phenotypes (ramified, hypertrophic, and bushy) in both the lesion and spared tissue using the optical fractionator method of unbiased stereology [53] . Spinal cord sections from the 7-d rat study, spaced 1 mm apart from 5 mm caudal to 5 mm rostral the injury epicenter, were stained for ionized calcium-binding adaptor molecule 1 (Iba-1) and DAB. Contours outlining spared and lesion tissue were traced onto each section, based on GFAP staining of adjacent sections. The optical dissector had a size of 50 μm×50 μm, a height of 10 μm, and a guard zone of 4 μm from the top of the section. A grid spacing of 250 μm in the x-axis and 250 μm in the y-axis was used. Microglia were counted throughout both spared and lesion tissue. Microglial phenotypic classification was based on the length and thickness of the projections, the number of branches and the size of the cell body, as previously described [54, 55] . The volume of the region of interest was measured using Cavalieri estimator method. The estimated number of microglia in each phenotypic class was divided by the volume of the region of interest to obtain the cellular density expressed in counts/mm 3 . Neurolucida software (MBF Biosciences) was used to create reconstructions of microglia at different stages of activation after injury by tracing the cell bodies and dendrites [55] . Microglia were outlined using the live image setting so that the width of the dendrites could be traced while focusing on the section. The cell bodies were outlined using the contour tool followed by tracing of individual dendrites, using the dendrite line tool.
Stereology and GFAP + Cell Counts
Eight or nine representative subjects (based on BBB score) from the 5-week rat study were selected from each treatment group for quantification of astrocytes (GFAP + cells) using the optical fractionator method with the aid of StereoInvestigator Software. Sections spaced 1 mm apart from 5 mm caudal to 5 mm rostral the injury epicenter were included for counting [43] . A sampling grid comprised of 250 μm×250 μm squares (150 μm×150 μm squares in the gray matter for GFAP + cells) was laid over each section. Cells were counted in a 50 μm×50 μm counting frame within each square of the counting grid with a height of 10 μm and a guard zone of 4 μm from the top of the section. GFAP + cells were counted throughout the entire section.
Immunofluorescent Staining and Quantification
Immunohistochemistry was performed on brain and spinal cord coronal sections at specified distances rostral and caudal to the injury epicenter. Standard fluorescent immunocytochemistry on serial, 20-μm thick sections was performed as described previously [56] . The following primary antibodies were used: rabbit anti-Iba-1 (1:1000; Wako Chemicals, Richmond, VA, USA), mouse anti-cyclin D1 (1:500; Neomarker, Fremont, CA, USA), rabbit anti-cysteine-cysteine chemokine ligand (CCL)21 (1:200; Abcam, Cambridge, MA, USA), mouse anti-CD68 (ED1, 1:500; AbDerotec, Raleigh, NC, USA). Fluorescent-conjugated secondary antibodies (Alexa 488-conjugated goat antimouse or rabbit, 1:1000; Molecular Probes, Grand Island, NY, USA) were incubated with tissue sections for 1 h at room temperature. Cell nuclei were labeled with 4', 6-diamidino-2-phenylindole (1 μg/ml; Sigma, St. Louis, MO, USA). Finally, slides were washed and mounted with an anti-fading medium (Invitrogen, Grand Island, NY, USA). Immunofluorescence microscopy was performed using a Leica TCS SP5 II Tunable Spectral Confocal microscope system (Leica Microsystems, Bannockburn, IL, USA). The images were processed using Adobe Photoshop 7.0 software (Adobe Systems, San Jose, CA, USA). All immunohistological staining experiments were carried out with appropriate positive control tissue, as well as primary/secondary-only negative controls.
For quantitative image analysis, digital images at 20× magnification were captured from the PO, VPL, ventral posteromedial (VPM), and centrolateral (CL) nuclei, based on atlas boundaries and using a confocal laser-scanning microscope (n=3 sections/location/time point/rat for 6-8 rats/group). These were analyzed to quantify Iba-1-and cyclin D1-expressing cells with ImageJ software (1.43; NIH, Bethesda, MD, USA). Based on the gray values of digital images, the threshold was set to display only fluorescence-positive pixels. Positive pixels of units of cell size (>7 μm diameter) were counted to estimate number of positive cell-sized particles [21, 57] . In addition, the number of ED1 + /Iba-1 + cells were counted for each animal by an average of bilateral counts on each of 2 spinal cord sections (4 samples) at a predefined area of superficial lumbar dorsal horn.
Western Blots
Animals were deeply anesthetized with sodium pentobarbital (100 mg/kg i.p.), and spinal cord tissue (5 mm) centered on the injury site was removed and stored at -80°C for processing. The tissue was homogenized (a glass on glass) and sonicated in radioimmunoprecipitation assay buffer (Sigma), and then centrifuged at 20,600×g for 20 min at 4°C. The supernatant was removed and protein concentration was determined using the Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL, USA) with a bovine serum albumin standard. Each sample contained proteins from one animal. Equal amounts of protein were electrophoretically separated on 4-12 % NuPAGE Novex Bis-Tris gradient gels (Invitrogen) and transferred to nitrocellulose membranes (Invitrogen). After blocking in 5 % nonfat milk for 1 h at room temperature, membranes were incubated with respective antibodies against cysteine-cysteine chemokine ligand 21 (CCL21) (polyclonal, 1:500; Abcam), CDK4 (polyclonal, 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), cyclin D1 (polyclonal, 1:500; Neomarker), cyclin E (monoclonal, 1:500; Santa Cruz Biotechnology), galectin 3 (monoclonal, 1:1000; Abcam), ionized calcium-binding adaptor molecule 1 (polyclonal, 1:1,000; Wako Chemicals), GFAP (monoclonal, 1:10,000; Chemicon, Billerica, MA, USA), and proliferating cell nuclear antigen (PCNA) (polyclonal, 1:500; Santa Cruz Biotechnology) overnight at 4°C followed by horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Sykesville, MD, USA) for 1.5 h at room temperature. The immunoreactivity was detected using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific), and quantified by band densitometry of scanned films using the Gel-Pro Analyzer program (Media Cybernetics, Gaithersburg, MD, USA). Some blots were further stripped in a stripping buffer (Thermo Scientific) for 45 min at 55°C. The loading and blotting of equal amounts of protein were verified by re-probing the membrane with anti-glyceraldehyde 3-phosphate dehydrogenase (monoclonal, 1:1000; Chemicon).
Primary Microglia Culture and Conditioned Medium Preparation
Primary microglia were cultured from the cerebral cortex of 1-3-day-old rats as described [58] . In brief, cerebra were dissected and chopped with microscissors. After incubation with 0.125 % trypsin/ethylenediaminetetraacetic acid for 10 min at 37°C, the tissue was triturated and centrifuged at 500×g for 10 min. The resulting cell suspension was plated on 150 cm 2 tissue culture flasks that had been coated with poly-d-lysine (50 μg/ml, 70-150 kDa). The cells were grown in Dulbecco's Modified Eagle's Medium/F12 (Invitrogen) supplemented with 10 % fetal bovine serum (Invitrogen), 1 % Pen/Strep at 37°C with 5 % carbon dioxide. When the cells had grown to confluence, the flasks were shaken at 100 rpm for 1 h at 37°C to isolate microglia. Then, the cells were re-plated in 3.5 cm dishes. When microglia had reached confluence, lipopolysaccharide (LPS) (50 ng/ml) was applied to the dish for 24 h. Cells were then washed twice with pre-warmed PBS, and the culture medium was replaced. After a 2-day culture period, the medium was collected and filtered to be used as conditioned culture medium.
Primary Cortical Neuronal Culture
Rat primary cortical neuronal cultures were derived from E18 rat cortices, as previously described [56] . Cells were seeded at a density of 1×10 6 cells/cm 2 onto poly-dlysine-coated 6-well plates. Arabinofuranosyl cytidine was added 24 h after plating (5 μM). The culture was maintained in serum-free conditions using Neurobasal medium supplemented with 2 % B27, 25 mM Naglutamate, and 0.5 mM L-glutamine. Conditioned media harvested from the stimulated microglia was added to the significantly (p<0.001) attenuated the development of hyperesthesia after SCI. Oneway analysis of variance with Bonferroni adjustment revealed that SCI vehicle-treated animals (n=12) were significantly different from SCI animals treated with CR8 (p=0.022, n=11) and sham controls (vehicle, p=0.001, n=9; CR8, p<0.001, n=13). No other between-group differences were significant. Note that data in panels (a) and (b) are derived from different experimental groups cultured neurons at 7 days in vitro for a further 48 h. Whole-cell extracts were prepared for Western blotting, as described previously [58] .
Microglia Proliferation Assay
In vitro cell proliferation was assessed in microglia cultures by using a microculture [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma)]-based colorimetric assay. Briefly, freshly purified cells were plated at 30,000 cells/well in a 96-well plate. After pre-treatment for 1 h with CR8, roscovitine (Tocris Bioscience, Ellisville, MO, USA), flavopiridol (Santa Cruz Biotechnology), or vehicle, the cells were stimulated with LPS 50 ng/ml for 24 h. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added to cell cultures to give a final concentration 357 μg/ml, and the samples were incubated for 2 h at 37°C in 5 % carbon dioxide. The supernatant was then removed and the formazan crystals produced in viable cells were solubilized with 150 μl dimethyl sulfoxide. Finally, the absorbance of each well was read at 570 nm using a microplate reader. of variance with Bonferroni correction revealed that spontaneous activity (e) was significantly (p=0.0053) higher after SCI, as well as in animals with hyperesthesia (n=54 cells), compared with those without hyperesthesia (p=0.041, n=27) and sham control (p=0.02, n=15), but not between those without hyperesthesia and sham operations. Similarly, sensory-evoked activity (f) is increased significantly (p=0.0084) after SCI. PO activity in SCI animals with hyperesthesia was significantly higher compared with shams (p=0.019), whereas activity in animals without hyperesthesia was not significantly higher compared with that in animals with hyperesthesia or in shams Nitric Oxide Assay
The nitrite in the culture supernatant was measured as an indicator of nitric oxide (NO) production using the Griess reagent assay (Invitrogen), according to the manufacturer's instructions.
Data Analysis
Unless indicated otherwise, results are expressed as mean ± SEM, where "n" is the number of individual animals. Statistical comparisons included two-way analysis of variance (ANOVA) with repeated measures in behavioral experiments, Student's t test or one-way ANOVA with the Tukey or Newman-Keuls post-hoc test in lesion volume, WM sparring, cell counting, and Western blot analysis. All statistical analyses were conducted by using the GraphPad Prism Program, Version 3.02 for Windows (GraphPad Software, La Jolla, CA, USA). In all cases, p<0.05 was considered statistically significant.
Results

Administration of CDK Inhibitor CR8 Reduces SCI-Induced Hyperesthesia
To test for SCI pain, the threshold of rats' responses to mechanical stimuli applied to the plantar surface of the hindpaw was examined. Testing began 3 or more weeks after SCI because in both humans and rodents with SCI, SCI pain develops after a latent period [11, 28, 35, 41] . As seen in Fig. 1(a) , there was a significant (p=0.0005; t test) decrease in the threshold for withdrawal from mechanical stimuli of SCI animals (mean decrease=-21.5±6.7 %, n=16). In contrast, the thresholds of sham-operated controls did not change significantly (mean=12.1±5.5 %, n=12). To estimate the incidence of animals that developed SCI pain, we defined hyperalgesic states as decreases in withdrawal threshold that exceed 20 % of mean baseline values. Using this criterion, 63 % (10 of 16) of the animals developed SCI pain, a value similar to that reported in previous studies using similar approaches [17, 59, 60] . These values likely underestimate the extent and incidence of hyperesthesia because SCI animals had severe motor deficits (described below) that hinder their ability to withdraw from mechanical stimuli.
To test the potential prophylactic effect of cell cycle inhibition on the development of post-injury hyperesthesia, we systemically administered CR8 to a separate group of SCI animals [30, 56] . CR8 treatment significantly improved behavioral outcomes (Fig. 1b) . The percent change in withdrawal thresholds in SCI animals that received CR8 (mean=-7.9±7.8 %, n=11) was statistically indistinguishable (p=0.17) from that of sham-operated rats that also received CR8 (mean=11.9±5.7 %, n=13), suggesting that CR8 treatment provided protection from the development of SCI pain. Consistent with this conclusion, the percent change in withdrawal threshold of SCI animals that received CR8 was significantly (p=0.02) lower than that in SCI rats that received vehicle injections (mean=-35.3±3.3 %, n=12). Further, there was a significant, negative correlation (p=0.02; Pearson's X 2 ) between the presence of hyperesthesia (defined as a >20 % decrease in threshold) and CR8 treatment: Hyperesthesia was less common in SCI animals that received CR8 (36 %; 4 of 11) than in SCI rats that received vehicle injections (83 %; 10 of 12). Administration of CR8 to sham-operated rats (n = 13) had no significant effect on their withdrawal thresholds compared with those receiving vehicle injections (p=1.0). These findings demonstrate that inhibition of the cell cycle pathway by CR8 limits posttraumatic hyperesthesia. Fig. 3 Treatment with the cell cycle inhibitor CR8 attenuates the effects of contusion SCI on neuronal activity in posterior nucleus. Group data show a significant effect of treatment on both spontaneous (a, p=0.0004) and sensory-evoked activity (b, p=0.0001). (a) One-way analysis of variance with Bonferonni correction revealed that spontaneous firing rates in spinal cord injury (SCI) animals with vehicle treatment (n=33 cells) were significantly higher than those in SCI animals treated with CR8 (p=0.017, n=35 cells) and sham animals (vehicle, p=0.008, n=24; CR8, p<0.001, n=30). However, activity in SCI animals receiving CR8 was not significantly different from either sham group. (b) Similarly, evoked firing rates were significantly higher in SCI vehicle animals than those in SCI CR8 animals (p=0.001) and sham (vehicle, p=0.001; CR8, p=0.002). There was no difference between firing rates from SCI CR8 and either sham treatment condition Neuronal Activity in Thalamic PO is Increased After Spinal Cord Contusion and Reversed by CDK Inhibition
To further examine the role of cell-cycle activation in posttraumatic hyperesthesia and the development of SCI pain, we examined the effects of impact SCI and CR8 treatment on PO electrophysiology. We obtained single-unit, electrophysiological recordings from urethane-anesthetized rats, as previously described [24, 50, 61] . Consistent with our previous findings after electrolytic lesions of the spinothalamic tract [13] , SCI significantly increased both spontaneous and sensory-evoked responses of PO neurons, as evidenced by comparing peri-stimulus time histograms (Fig. 2a, b) . Group comparisons show that spontaneous firing rates of PO neurons in SCI rats ( Fig. 2c; 3 .0±0.4 Hz, n=81 neurons) are significant, and nearly 3-fold higher (p<10 -4 , t test) than those in sham-operated controls (1.1±0.2 Hz, n=15). Using our previous criterion for the presence of hyperesthesia (see above), comparisons of SCI rats with or without post-injury hyperesthesia, and sham-operated controls, showed significant differences (p=0.005, one-way ANOVA with Bonferroni correction) in PO spontaneous activity (Fig. 2e) . Betweengroup comparisons revealed a significant difference not only between SCI rats with hyperesthesia and sham-operated 
rat and from injured salineor CR8-treated rats. The SCI lesion is visible as a region with absence of glial fibrillary acidic protein/diaminobenzidine staining than the surrounding tissue. Scale bars=500 μm. (e, f) Neurological outcome was also evaluated using the Basso, Beattie and Bresnahan (BBB) score of hind limb locomotor function and the combined behavioral score (CBS), an evaluation of overall hind limb sensory-motor deficits. Both BBB and CBS tests showed significantly improved functional recovery in CR8-treated rats (n=15) compared with salinetreated rats (n=13). *p<0.05 compared with saline-treated group controls (p=0.020), but also between the two SCI groups (p=0.041), with a significant negative correlation between PO firing rates and percent change in mechanical withdrawal thresholds (Pearson's r=-0.29, p=0.004). Responses to innocuous tactile stimuli were also significant, and approximately 4-fold higher (p<10 -4 , t test) in SCI rats ( Fig. 2d; 2 .8±0.4 Hz, n=80) than shams ( Fig. 2d ; 0.7±0.1 Hz, n=15). Again, comparing responses from rats with or without post-traumatic hyperesthesia and those from sham-operated controls showed statistically significant differences ( Fig. 2f; p=0.0084) with a in the PO, as well as VPL, at both time points. (e) Quantification of pixel intensity for Iba-1 revealed significant microglial activation in both PO and VPL at 7 days and 8 weeks post-injury, as well as in the VPM at 8 weeks after SCI. These changes were remarkably suppressed by CR8 treatment. Microglial activation was not observed in the adjacent CL nucleus after SCI. n=3 sections/location/time point/rat for 6-8 rats/group. *p<0.05 vs Sham control; #p<0.05 vs vehicle (Veh) groups. Scale bars=500 μm for (b), and 100 μm for (c) and (d). CA1-3 (fields CA1-3 of Ammon's horn); DG (dentate gyrus); PoDG (polymorph layer dentate gyrus); LPMR (lat post thal nu, mediorostral); LDVL (laterodorsal thal nu, ventrolat); DLG (dorsal lateral geniculate nu); MDL (mediodorsal thal nu, lateral); Rt (reticular thal nu); PC (paracentral thal nu); VM (ventromedial hypoth nu); ZID (zona incerta, dorsal); ZIV (zona incerta, ventral); STh (subthalamic nu); Subl (subincertal nu); MePD (medial amyg nu. posterodorsal)
significant correlation between firing rates and percent change in baseline mechanical thresholds (Pearson's r=-0.26, p=0.0097). Thus, contusion SCI produces similar abnormalities in PO thalamus as those seen after selective electrolytic lesion of the spinothalamic tract [24] , consistent with the hypothesis that changes of thalamic activity are causally related to development of SCI pain [13, 62] .
To test the effect of cell cycle inhibition on the development of thalamic abnormalities, we compared spontaneous firing rates of PO neurons from 4 groups: rats with SCI that received CR8 treatment or vehicle injections, and shamoperated rats that received either CR8 or vehicle (Fig. 3) . Spontaneous firing rates were significantly (p=0.017; Fig. 3a ) lower in the SCI group that received CR8 (1.9±0.2 Hz, n=35 neurons) than in the SCI group that received vehicle treatment (3.5±0.6 Hz, n=33 neurons). Spontaneous firing rates in the SCI vehicle group were significantly different (all p ≤0.008) compared with those in PO neurons from rats that received sham surgery and either CR8 (1.3±0.2 Hz, n=30 neurons) or vehicle treatments (1.6±0.3 Hz, n=24 neurons). CR8 treatment also limited the effects of SCI on evoked responses of PO neurons (Fig. 3b) . The magnitude of evoked firing rates was significantly (p=0.001) lower in the SCI group that received CR8 (1.5±0.2Hz, n=33 neurons) than in the SCI group that received vehicle treatment (3.4±0.6 Hz, n=34 neurons). Evoked firing in the SCI vehicle group was also significantly different (all p ≤0.002) than those in PO neurons from rats that received sham surgery and either CR8 (1.5±0.2 Hz, n=30 neurons) vehicle treatments (1.3±0.2 Hz, n=24 neurons). The significant negative correlation between firing rate and percent change in baseline mechanical withdrawal threshold was maintained across treatment conditions in this group of animals (spontaneous, Pearson's r=-0.28, p=0.0017; sensory-evoked, Pearson's r=-0.27, p=0.0031).
These findings support the conclusion that cell cycle inhibition limits the changes in thalamic neuronal excitability in rats with post-traumatic hyperesthesia. That CR8 treatment reduces both SCI-induced hyperesthesia and the associated thalamic changes is consistent with the hypothesis that these PO abnormalities are causally related to the development of post-traumatic hyperpathia Cell Cycle Inhibition Increases Spared WM Area, Reduces Lesion Volume, and Favors Functional Recovery After SCI We compared the extent of WM sparing and the volume of spinal lesions in SCI rats that received either CR8 treatment or vehicle injections. Figure 4 (a) depicts representative eriochrome stained sections and illustrates the differences in spared WM area between vehicle-and CR8-treated animals. CR8 treatment significantly increased WM area (Fig. 4-b) . SCI-induced lesion volume/cavity formation was measured with GFAP/DAB staining 5 weeks after SCI, and analyzed by stereological techniques. There was significantly reduced lesion size and greater preservation of the WM in animals treated with CR8 than in vehicle-treated animals (Fig. 4d) . Group analysis showed that lesion volume was significantly smaller in CR8-treated rats (9.63±0.37 mm 3 , n=10) compared with that in vehicletreated controls (15.40±2.00 mm 3 , n=8, Fig. 4c ). This reduction occurred in both white and gray matter, with an overall decrease in cavity formation and tissue loss. Neurological outcome was also evaluated using the BBB and CBS scores; each test showed significantly improved functional recovery in CR8-treated rats (Fig. 4e, f) .
Chronic Microglial Activation Occurs in Selective Thalamic Sites (Including PO) After SCI and is Attenuated by CDK Inhibition
Given that microglial activation in the VPL of the thalamus has been implicated in the development of chronic pain after spinal cord contusion [21] , we assessed the potential influence of CDK inhibition on microglial activation of the thalamus following SCI. Immunostaining was performed for inflammatory marker Iba-1 at 7 days and 8 weeks after SCI. Locations of PO and the adjacent nucleus, including the VPM, VPL, and CL in the thalamus, were identified from the Paxinos and Watson atlas (see Fig. 5a ). Immunostaining of brain sections from both intact and SCI animals at 7 days post-injury revealed the presence of Iba-1 + microglia in PO. Importantly, we found a significant increase in the number of these cells in the PO of injured animals compared with sham controls (Fig. 5b) . Moreover, the predominant morphotype of microglia in intact tissue displayed small compact cell bodies bearing long thin ramified processes (Fig. 5b (1), c (1) ). After SCI, activated Iba-1 + microglia exhibited larger cell bodies with shorter and thicker projections and retraction of processes at 7 days post-injury ( Fig. 5c (2) ); these activated microglia occurred not only in PO but also in VPL thalamus. Thus, we confirmed a previous report that activated microglia occur in VPL [21] , but demonstrate here that they occur also in "higher order" thalamic nuclei, such as PO. At 8 weeks after injury, activated microglia became progressively There was no significant difference in the number of total microglia and 3 microglial phenotypes in the lesion area, as well as ramified microglia in the spared tissue across groups. CR8 treatment demonstrated significantly reduced numbers of activated microglia in the spared tissue compared with SCI Veh rats (*p<0.05 SCI CR8 vs SCI Veh; n=4-5/group). GAPDH=glyceraldehyde 3-phosphate dehydrogenase; Gal3=galectin 3 more pronounced in terms of the numbers and pixel intensity ( Fig. 5b (3), c(3) ), suggesting prolonged activation of microglia in the thalamus. Notably, these changes were significantly attenuated by CR8 treatment (Fig. 5 (d), (e) ). We did not observe any significant difference in microglial activation in the adjacent CL nucleus after SCI. Significant increase of the pixel intensity in the VPM was observed at 8 weeks after SCI compared with sham animals, but changes were less than those observed in either the PO or VPL. We did not observe any difference in GFAP + astrocytes in the PO between intact and SCI animals (data not shown).
SCI-Induced Gliopathy at the Injury Site is Suppressed by CR8 Treatment
Western blot was performed with the 5 mm spinal cord tissue centered on the injury site at 5 weeks after SCI. Expression levels of inflammatory and astrogliosis markers, Iba-1, galectin-3, and GFAP indicated a 3-5-fold increase in injured spinal cord extracts compared with sham tissue (Fig. 6a, b) . Stereological assessment of GFAP + cells showed a 3-4-fold increase from 5 mm caudal to 5 mm rostral the injury epicenter in the injured cords (Fig. 6c) . CR8-treated tissue showed significantly reduced levels for these markers in comparison with vehicle-treated tissue (Fig. 6a, b) . CR8 treatment significantly reduced the number of GFAP + cells at 5 weeks post-injury (Fig. 6c) . The total number of Iba-1 + microglial/macrophages was examined at 7 days after SCI when activation of these cells peaks during the early phase of cellular inflammation [25, 63, 64] . SCI caused a 3-4-fold increase of total Iba-1 + cells; however, such changes were not altered by CR8 treatment (Fig. 6d) . Further, we examined activated microglial/macrophages in the preserved tissue, as well as in the central lesion area, where circulating macrophages infiltrate after SCI. Figure 6e shows the lesion boundary between spared tissue and lesion cavity, as indicated by GFAP staining. Representative images and reconstructions (Neurolucida) of the resting (ramified, small cell body with elongated and thin projections) and activated (hypertrophic, large cell body with shorter and thicker projections; bushy, multiple short processes that form thick bundles around enlarged cell bodies) are presented (Fig. 6f) . No significant differences were observed in the number of total or ramified microglia across the groups in both spared and lesion areas. Activated microglial phenotypes, including hypertrophic and bushy types, were significantly reduced in the spared tissue in CR8-treated animals compared with vehicle-treated tissue (p<0.05). In contrast, CR8 treatment did not significantly affect the number of activated microglial phenotypes in the central lesion area (Fig. 6g, h ).
CR8 Administration Reduces Inflammation in the Lumbar Dorsal Horn Following SCI
Microglial activation also contributes to the development and maintenance phases of chronic below-level pain after SCI [28, 65, 66] . To determine if the observed attenuation of below-level mechanical allodynia in CR8-treated rats may be related to the reduced activation of spinal microglial, spinal cord lumbar sections from injured rats perfused at 5 weeks after SCI were stained for ED1/Iba-1, and activated microglia within the superficial dorsal horn were quantified. ED1-positive reactive microglia were rarely seen in uninjured tissue (Fig. 7a) , but 5 weeks after SCI, ED1 + /Iba-1 + cells were significantly increased in the injured tissue compared with sham tissue, consistent with other reports [67] . Notably, there was a significant reduction in positively-stained cells in CR8-treated animals ( Fig. 7b ; p<0.05). Thus, decreased numbers of reactive microglia are found in the lumbar spinal dorsal horn in CR8-treated rats associated with reduced below-level mechanical allodynia in these animals.
SCI Causes Up-Regulation of Cyclin D1 and CCL21 Expression in the PO
To further investigate the involvement of the cell cycle pathway in SCI-induced thalamic abnormalities, we first examined whether up-regulation of cell cycle proteins occurs in the thalamus following SCI. Immunohistochemistry was performed to determine the distribution of cyclin D1 in the thalamus following SCI (Fig. 8b, c) . In the intact thalamus, immunoreactivity of cyclin D1 was weakly detected in some neurons ( Fig. 8a(1) ). At 8 weeks post-injury, numerous cyclin D1-positive cells were observed in not only PO ( Fig. 8a(2) ) but also in VPL (Fig. 8b) . Treatment with CR8 revealed a significant reduction of cyclin D1+ cells in these subregions of the thalamus (Fig. 8a(3), b) . We did not observe a significant increase in cyclin D1 + cells in the adjacent CL or VPM nuclei (Fig. 8b) .
Second, as the neuroimmune modulator CCL21 was reported to be up-regulated in the VPL after SCI and may serve to trigger thalamic microglial activation in association with hyperesthesia [21] , we investigated whether CDK inhibitor treatment alters CCL21 levels in PO after SCI. In the intact animal, immunoreactivity of CCL21 was weakly detected (Fig. 8c(1) ). At 7 days after SCI, CCL21 immunolabeling showed a clear increase in PO neuronal cell bodies and parenchyma ( Fig. 8c(2) ). There was a reduction of CCL21 signal at 7 days post-injury in CR8-treated animals ( Fig. 8c(3) ). Notably, a subset of cyclin D1 + cells were co-labeled with CCL21 ( Fig. 8(d) ).
Cell Culture Studies
To determine whether increased thalamic levels of cell cycle protein and CCL21 after SCI could be induced by local factors, conditioned medium (CM) from cultured microglia stimulated by LPS or saline were applied to primary neuronal cultures. We observed a significant increase in protein expression of cyclin D1 and CCL21 when the neurons were cocultured with LPS-treated CM compared with saline-treated CM (Fig. 9a, b) . Given that pre-treatment with CDK inhibitors such as flavopiridol and roscovitine significantly reduces microglial proliferation and activation in response to LPS, as indicated by a reduction in NO, we assessed the potency of CR8 compared with earlier purine analogs or flavinoid types of CDK inhibitors [33, 38, 68] . Pretreatment with CR8 in cultured microglia significantly attenuated LPS-induced microglial proliferation and NO release in a dose-dependent manner (Fig. 9c, d ). The effect of CR8 was similar to that of flavopiridol, a potent pan-CDK inhibitor, but with 10-20-fold higher potency than roscovitine, a more selective CDK inhibitor. Importantly, CM from CR8 treatment prior to incubation with LPS significantly reduced protein expression of cyclin D1 and CCL21 compared with the vehicle group (Fig. 9b) . Quantitative analysis of Western blots showed a marked upregulation of several key cell cycle proteins, including cyclins D1 and E, CDK4, and PCNA at 5 weeks following SCI (Fig. 10) . The up-regulation of cell cycle proteins was significantly attenuated in CR8-treated rats in comparison with vehicle-treated tissue (Fig. 10) .
Further, the expression of cell cycle-related proteins was examined in the lumbar spinal dorsal horn by immunohistochemistry. In the intact spinal cord, cyclin D1 was barely detected (Fig. 10g(1) ). At 7 days after SCI, cyclin D1 immunoreactivity was up-regulated in the injured tissue ( Fig. 10g(2) ). CDK4-and E2F1-positive cells were also increased in injured tissue (data not shown). Importantly, the up-regulation of these cell cycle-related proteins was clearly attenuated in the lumbar spinal dorsal horn in rats with CR8 treatment (Fig. 10g(3) ).
Discussion
In a rat spinal cord contusion model we show that cell cycle activation contributes to the development of chronic hyperesthesia after SCI, which is closely correlated to increased neuronal activity in the PO nucleus of the thalamus. Up-regulation of cell cycle pathways after SCI occurs not only at the thoracic injury site but also at thalamic pain regulatory sites, including PO and VPL, as well as in the lumbar dorsal horn. Increased CCL21 expression and microglial activation was found in the PO after SCI, and in vitro activated microglia up-regulate cell cycle proteins and CCL21 in primary cultured neurons; these changes are suppressed by inhibition of cell cycle activation both in vivo and in vitro.
Neuronal hyperexcitability in the PO thalamus has been associated with CPS after electrolytic lesions in the ventrolateral quadrant of the spinal cord [24] in which the ascending STT axons degenerate [69] . The PO receives somatosensory inputs from the STT and projects to the primary somatosensory cortex [70] [71] [72] [73] [74] [75] , which plays an important role in processing sensory-discriminative aspects of pain [76] [77] [78] [79] [80] . Here we show that SCI causes significant increases in both spontaneous firing rates and evoked responses in PO neurons, consistent with prior findings after electrolytic lesions of the spinothalamic tract [24] . Moreover, neurons from rats with SCI-related hyperesthesia demonstrate significantly higher neuronal activity than those without hyperesthesia with a significant, negative correlation between firing rates and change in mechanical + cells showed a significant increase in both PO and ventroposteriolateral nucleus (VPL) at 8 weeks (8w) postinjury. Treatment with CR8 revealed a remarkable reduction of cyclin D1 expression in these subregions of the thalamus. We did not observe a significant increase in cyclin D1 + cells in the adjacent centrolaterial (CL) or ventral posteromedial (VPM) nucleus. *p<0.05 vs sham control; #p<0.05 vs vehicle (Veh) groups. n=3 sections/location/time point/rat for 6-8 rats/group. (c) Immunoreactivity of CCL21 was weakly detected in the PO from intact animals (c1). At 7 days (7d) after SCI, CCL21 immunolabeling showed a clear increase in the PO, likely within neuronal cell bodies and parenchyma (c2). Importantly, we observed a reduction of CCL21 signal at 7 days post-injury in CR8-treated animals (c3). (d) A subset of cyclin D1 + cells (arrows, green) were co-labeled with CCL21 (arrows, red). Scale bars=500 μm for (a) and 100 μm for (c) and (d). DAPI=4',6-diamidino-2-phenylindole threshold across treatment groups, supporting a causal relation between increases in spontaneous and evoked PO activity and post-SCI hyperesthesia.
SCI-induced neurological effects, including SCI pain, reflect delayed injury-induced processes that contribute to tissue loss and neuroplasticity. These secondary injury processes include neuronal and oligodendroglial cell death, inflammation, and reactive astrogliosis [81, 82] . Post-traumatic CCA has been implicated in delayed neuronal and oligodendroglial apoptosis, reactive astrocytosis and formation of the glial scar, and microglial activation with release of inflammatory factors [34, 83] . Important mediators of CCA are CDKs, a group of small, serine/threonine kinases. We and others have previously found that SCI causes up-regulation of cell cycle pathways, including cyclins and CDKs at the primary lesion site [30, 40, 43, 83, 84] . Here we show that cell cycle proteins are up-regulated not only in the thoracic SCI site and caudal lumbar dorsal horn, but also in the thalamus, suggesting that CCA may contribute to SCIinduced hyperpathia through actions in these areas.
Remote microglial activation has been proposed as a critical mechanism for chronic and persistent pain syndromes after SCI, and in other central pain syndromes [29] . SCIinduced microglial activation in the ventral thalamus has been correlated to lowered nociceptive thresholds through a mechanism involving the chemokine CCL21, a potent microglial activator [21] . Here we report microglial activation in the PO, as well as the VPL after SCI. Whether the microglial changes correlate with the initiation of hyperesthesia could not be . (a, b) CM from cultured microglia stimulated by LPS or saline were applied to primary neuronal culture. Protein expression of cyclin D1 and CCL21 was up-regulated when the neurons were co-cultured with LPS-treated CM compared with saline-treated CM (*p<0.05 compared with control group, n=4 from 3 independent cultures), and significantly attenuated with CM from CR8 treatment prior to incubation with LPS (#p<0.05 compared with LPS group, n=4 from 3 independent cultures). (c, d) Pre-treatment with CR8 in cultured microglia significantly attenuated LPS-induced both microglial proliferation and release of nitric oxide in a dosedependent manner. The effect of CR8 was similar to that of flavopiridol, but 10-20-fold higher potency than roscovitine (*p<0.05 compared with LPS alone-treated group, n=4 from 4 independent cultures). GAPDH=glyceraldehyde 3-phosphate dehydrogenase determined because before 4 weeks post-injury reliable somatosensory testing is not possible owing to locomotor deficits that preclude testing of nociceptive thresholds. CCL21 levels were also elevated in the PO at 7 days post-SCI, and partly co-labeled with cyclin D1. It is possible that CCL21 activates resident microglia in the PO, which contributes to the nociceptive effects mediated by neuronal activity in this region. CCL21 signal was increased in cultured neurons exposed to high concentrations of glutamate [85] and in excitatory neurons of the dorsal horn, and in spinal parenchyma after SCI [21] . Here we show that CM derived from activated microglia in vitro induces CCL21, as well as cell cycle protein expression in cultured neurons, suggesting that the increased CLL21 levels in the thalamus after SCI may, in part, reflect the observed local microglial activation. This conclusion would be consistent with the report of Zhao et al. [21] showing that CCL21 levels were not completely abolished by cord transection rostral to both the injury site and lumbar enlargement after SCI. Thus, CCL21 + cells were found in the dorsal horn of intact rat (g1). Cyclin D1 + cells increased 7 days after SCI (g2) and was attenuated in CR8-treated animals (g3). Scale bar=100 μm. *p<0.05 SCI groups vs sham groups; # p<0.05 SCI CR8 vs SCI vehicle (Veh); n=4-5/group. GAPDH=glyceraldehyde 3-phosphate dehydrogenase. PCNA proliferating cell nuclear antigen may be an important source, at least in part, for chronic thalamic microglial activation that maintains thalamic neuronal hyperactivity associated with persistent SCI pain. Cell cycle inhibition by CR8 decreased CCL21 levels in the PO after SCI, as well as in cultured neurons exposed to effluent from LPS-treated microglia. Further investigation is required to elucidate the mechanisms by which cell cycle inhibition modulates CCL21 signals after SCI.
SCI-induced astrogliosis and chronic inflammation in the lesion site are believed to contribute to glial scar formation and the progressive spinal cord tissue loss (including the WM that contains the STT) [30, 64, 86] . Our findings demonstrate that the selective and potent CDK inhibitor, CR8, significantly attenuates secondary tissue damage and related neurological dysfunction after impact spinal cord trauma, consistent with prior work demonstrating the neuroprotective effects of other cell cycle inhibitors after SCI [34, 43, 84] . CR8 significantly attenuated activated microglial phenotypes in the spared tissue and increased WM sparing including the ventrolateral quadrant that contains the STT. To what extent this effect serves to modulate post-injury hyperesthesia is speculative, but multisegmental anti-inflammatory actions at both caudal and supratentorial sites likely contributes to the striking ability of CDK inhibition to limit post-traumatic hyperesthesia.
Gliopathy in the lumbar dorsal horn may serve to maintain hyperexcitability of nociceptive neurons associated with hyperesthesia that follows SCI [28] . Thus, both spinal and thalamic mechanisms may be important in the genesis of pain and allodynia following SCI. We have previously demonstrated that treatment with cell cycle inhibitors markedly reduces chronic post-traumatic microglial activation at lesion sites. Here, we show, for the first time, that CCA contributes to remote microglial activation after SCI, including the thalamus and lumbar spinal dorsal horn, as evidenced by reduction of microglia activation in these areas following CCA inhibition. CR8 limited the development of hyperesthesia after SCI with an associated reduction in neuronal activity in the PO. These effects may reflect suppression of microglial activation that may contribute to changes in thalamic plasticity after injury. Microglia have multiple phenotypes: M1 is associated with cytokine release and neurotoxicity; M2 can modulate neuroplasticity. To what extent the ability of the CDK inhibition to reduce post-traumatic thalamic plasticity reflect its effects on M1 or M2 phenotypes requires further study.
Together, our data suggest that neurophysiological changes in the PO thalamus may contribute to SCI pain. These effects appear to be mediated in part by CCA, which may also contribute to post-injury hyperesthesia by mediating astroglial and microglial actions in the spinal cord. Given the proposed roles for CCA in other neuropathic pain models, it is plausible that activation of cell cycle pathways also represents a more generic mechanism relevant to other neuropathic pain states.
